162
Participants
Start Date
February 23, 2021
Primary Completion Date
May 16, 2022
Study Completion Date
August 25, 2023
Atezolizumab
Atezolizumab will be administered intravenously at a fixed dose of 1200 mg on Day 1 of each 21-day cycle.
Bevacizumab
Bevacizumab will be administered at a dose of 15 mg/kg intravenously on Day 1 of each 21-day cycle after atezolizumab.
Placebo
Placebo matching bevacizumab will be administered intravenously on Day 1 of each 21-day cycle after atezolizumab.
Cisplatin
Cisplatin will be administered intravenously at a dose of 25 mg/m\^2 on Days 1 and 8 of each 21-day cycle for Cycles 1-8.
Gemcitabine
Gemcitabine will be administered intravenously at a dose of 1000 mg/m\^2 on Days 1 and 8 of each 21-day cycle for Cycles 1-8.
National Taiwan Uni Hospital; Dept of Oncology, Taipei
CHA Bundang Medical Center, Gyeonggi-do
Istituto Clinico Humanitas - Humanitas Cancer Center, Rozzano
University of Virginia, Charlottesville
Duke Cancer Center, Durham
Hospital Ramon y Cajal; Servicio de Oncologia, Madrid
Complejo Hospitalario de Navarra; Servicio de Oncologia, Pamplona
Complejo Hospitalario de Orense; Servicio de Oncologia, Ourense
Sunpasitthiprasong Hospital; Oncology and/or Hematology, Ubon Ratchathani
Koc Universitesi Hastanesi; T?bbi Onkoloji, Zeyt?nburnu
IOV - Istituto Oncologico Veneto - IRCCS; Oncologia Medica II, Padua
Sarah Cannon Research Institute / Tennessee Oncology, Nashville
Srinagarind Hospital; Medical Oncology Unit, Khon Kaen
"Azienda Ospedaliero Universitaria di Bologna; Istituto di Ematologia Lorenzo e Ariosto Seragnoli", Bologna
Inonu University Medical Faculty Turgut Ozal Medical Center Medical Oncology Department, Malatya
Hospital Universitario Miguel Servet; Servicio Oncologia, Zaragoza
Maharaj Nakorn Chiang Mai Hosp; Oncology Unit, Chiang Mai
SI Institute of general&urgent surgery n/a Zaytseva V.T NAMSU, Kharkiv
?Kharkov Regional Oncology Center, Kharkiv
Fondazione Pascale; U.O. Sperimentazioni Cliniche, Napoli
City of Hope Cancer Center, Duarte
"SBIH Moscow Clinical Scientific and Practical Center named after A.S. Loginov of DHM", Moskva
Taipei Veterans General Hospital; Department of Oncology, Taipei
"FSBI National Medical Research Center of Oncology N.N. Blokhin?", Moscow
First Moscow State Medical University n.a. I.M. Sechenov, Moscow
GBUZ Saint Petersburg Clinical Research Center of Specialized Types of Care (Oncology), Saint Petersburg
Zhongshan Hospital Fudan University, Shanghai
Sir Run Run Shaw Hospital Zhejiang University, Hangzhou
Nanfang Hospital, Southern Medical University, Guangzhou
Massachusetts General Hospital, Boston
Queen Mary Hospital; Dept. Of Haematology & Oncology, Hong Kong
Prince of Wales Hosp; Dept. Of Clinical Onc, Shatin
SP ZOZ Wojewódzki Szpital Specjalistyczny nr 4; Oddzial Onkologii Klinicznej, Bytom
Uniwersyteckie Centrum Kliniczne; Klinika Onkologii i Radioterapii, Gdansk
Szpital Wojewódzki im. Miko?aja Kopernika; Oddzia? Dzienny Chemioterapii, Koszalin
NIO im Marii Sklodowskiej-Curie; Klinika Onkologii i Radioterapii, Warsaw
Dolno?l?skie Centrum Onkologii; Oddzia? Onkologii Klinicznej i Chemioterapii, Wroc?aw
Seoul National University Bundang Hospital, Seongnam-si
Seoul National University Hospital, Seoul
Asan Medical Center, Seoul
Samsung Medical Center, Seoul
Hospital Universitari Vall d'Hebron; Oncology, Barcelona
Adana Ac?badem Hospital Oncology Department, Adana
Memorial Ankara Hastanesi, Ankara
"SI Shalimov National Institute of Surgery and Transplantation of Nat.Acad of Med.Sci of Ukraine", Kyiv
Beatson West of Scotland Cancer Centre, Glasgow
Royal Free Hospital, London
Churchill Hospital, Oxford
Royal Marsden Hospital (Sutton), Sutton
Hoffmann-La Roche
INDUSTRY